Immucare Diagnostics Private Limited - Due diligence report

A 360° intelligence report on Immucare Diagnostics Private Limited: trust score, financial health, credit view, compliance, directors, growt…

2019-04-11 Ernakulam, Kerala Active Unlisted
Share
ID Immucare Diagnostics Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Immucare Diagnostics Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
70/100
Trust Score
Moderate

Immucare Diagnostics Private Limited is assessed as Moderate with a Trust Score of 70/100. Immucare Diagnostics Private Limited is an active private limited indian non-government company incorporated in 2019, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 22 Jul 2026 from the latest processed filings. Immucare Diagnostics Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
30/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 70/100 Moderate
  • No open charges - unencumbered balance sheet.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 85/100
NameDIN / PANDesignationAppointedTenureDIN status
SURYAPRAKASAM VEDAM LAKSHMI RAMPRASAD 01234567 Director 01/04/2018 6 yrs Approved
BALAMANIAMMA MADATHINKAL RAGHAVAN NAIR 01234567 Director 01/04/2018 6 yrs Approved
SURAJIT CHAKRABARTTY 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 3 director exit(s) in the last 3 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Medgenome Labs Limited
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Medgenome Labs Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 55
Growth signals & trust indicators
Revenue acceleration: +38% over 3 year(s).
Operating for 7 years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Negative net worth.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment66/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view56/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 10 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
29 Sep 2024
Director ceased
SURYAPRAKASAM VEDAM LAKSHMI RAMPRASAD
Director ceased
SURAJIT CHAKRABARTTY
26 Mar 2024
Director appointed
SURYAPRAKASAM VEDAM LAKSHMI RAMPRASAD (Director)
20 Feb 2024
Director ceased
PADMANABHA D SHENOY
25 Jan 2024
Director appointed
SURAJIT CHAKRABARTTY (Director)
31 Dec 2020
Director ceased
SREEDHAR SANTHOSH
11 Apr 2019
Incorporated
Registered with Roc Ernakulam
Director appointed
BALAMANIAMMA MADATHINKAL RAGHAVAN NAIR (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 3 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Rayah Impex Private Limited U74999MH2016PTC283567 Mumbai, Maharashtra, India
Kria Infotech Private Limited U72200TG2006PTC051605 Hyderabad, Telangana, India
Gramin Health Care U93090HR2011FTC044187 Gurgaon Kty., Haryana, India
Star City Multispeciality Hospital Private Limited U85110MH2010PTC205323 Kalayn, Maharashtra, India
Ajit Scanning And Diagnostic Centre Pvt.Ltd. U99999MH1993PTC070597 Kalyan, Maharashtra, India
Genepowerx U85320TG2019PTC133214 Hyderabad, Telangana, India
Medium Healthcare U85100TG2008PTC060965 Hyderabad, Telangana, India
Maclowin Lifescience Private Limited U24230RJ2016PTC055044 Jaipur, Rajasthan, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Immucare Diagnostics Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Immucare Diagnostics Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Immucare Diagnostics Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Immucare Diagnostics Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Immucare Diagnostics Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Immucare Diagnostics Private Limited an active company?

Immucare Diagnostics Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Immucare Diagnostics Private Limited financially healthy?

Immucare Diagnostics Private Limited has a Financial Health Score of 30/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Immucare Diagnostics Private Limited?

Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Immucare Diagnostics Private Limited?

The ultimate holding entity is Medgenome Labs Limited. 3 active director(s) are on record.

Does Immucare Diagnostics Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Immucare Diagnostics Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Immucare Diagnostics Private Limited?

Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.